Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - lumacaftor, quantity: 100 mg; ivacaftor, quantity: 125 mg - granules - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; povidone; sodium lauryl sulfate; hypromellose acetate succinate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - human immunoglobulin g, quantity: 9000 mg - solution - excipient ingredients: glycine; polysorbate 80; water for injections - indications for subcutaneous administration (scig),xembify? is indicated as replacement therapy in adult and paediatric patients for:,- primary immunodeficiency diseases (pid),- symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - human immunoglobulin g, quantity: 900 mg - solution - excipient ingredients: glycine; polysorbate 80; water for injections - indications for subcutaneous administration (scig),xembify? is indicated as replacement therapy in adult and paediatric patients for:,- primary immunodeficiency diseases (pid),- symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - human immunoglobulin g, quantity: 3600 mg - solution - excipient ingredients: glycine; polysorbate 80; water for injections - indications for subcutaneous administration (scig),xembify? is indicated as replacement therapy in adult and paediatric patients for:,- primary immunodeficiency diseases (pid),- symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

grifols australia pty ltd - human immunoglobulin g, quantity: 1800 mg - solution - excipient ingredients: glycine; polysorbate 80; water for injections - indications for subcutaneous administration (scig),xembify? is indicated as replacement therapy in adult and paediatric patients for:,- primary immunodeficiency diseases (pid),- symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

vertex pharmaceuticals australia pty ltd - lumacaftor, quantity: 75 mg; ivacaftor, quantity: 94 mg - granules - excipient ingredients: croscarmellose sodium; hypromellose acetate succinate; microcrystalline cellulose; povidone; sodium lauryl sulfate - orkambi is indicated for the treatment of cystic fibrosis (cf) in patients aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.

Filipini - angleščina - FDA (Food And Drug Administration)

agio pharamceuticals limited - drug - silver sulfadiazine - topisulfa

Filipini - angleščina - FDA (Food And Drug Administration)

agio pharamceuticals limited - drug - fusidic acid - fucelcid

Filipini - angleščina - FDA (Food And Drug Administration)

cadila pharamceuticals limited - drug - montelukast (as sodium) - aerokids

Filipini - angleščina - FDA (Food And Drug Administration)

akums drugs & pharmaceuticals ltd. (plant iii-injectables) - drug - metronidazole - promeddazole